Personalized radiation for oropharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a personalized approach to radiation therapy for oropharyngeal cancer. The goal is to safely reduce the amount of radiation to healthy lymph nodes, which may lower side effects while still effectively treating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed cancer of the oropharynx (back of the throat, including tonsils or base of tongue) that hasn't been treated yet.
- You need to be scheduled for radiation therapy (with or without chemotherapy) that includes some healthy lymph nodes in the neck.
- You must be 18 years or older and able to take care of yourself (ECOG score less than 3).
- You need to have a recent PET-CT scan (or an MRI if PET isn't possible) to check the extent of the cancer.
- You cannot have had previous surgery, radiation, or chemotherapy for another head or neck cancer, and the cancer must not have spread to distant parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an approach called “adaptive radiotherapy,” where the radiation plan may be adjusted based on how your tumor and anatomy look during treatment. It is for adults with biopsy-proven oropharyngeal (throat) squamous cell carcinoma who are planning curative radiation, with or without chemotherapy.
This trial tests whether giving less radiation after surgery is safe and effective for people with early-stage HPV-related throat cancer. It aims to reduce side effects while still controlling the cancer.
This study tests whether shrinking the “planned radiation area” (elective treatment volumes) can still treat p16-positive oropharyngeal cancer effectively. It may help reduce unnecessary radiation to nearby healthy tissues while keeping the cancer treatment curative.
This Phase 2 study uses HPV test results from your tumor to safely lower (de-intensify) the strength of radiation for some HPV-positive oropharyngeal throat cancers. It aims to reduce side effects while keeping cancer control effective.
This trial compares a personalized, shorter course of radiation therapy to the standard longer course for people with HPV-positive throat cancer. The goal is to see if personalized treatment is just as effective while reducing side effects.
This trial tests a treatment plan that may lower (de-escalate) therapy intensity for certain p16+ or HPV-positive throat cancers. It uses PET scan results and tumor features to try to keep cancer control while reducing side effects.
Hear when a new Oropharynx Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.